Bank of America Corp DE Reduces Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Bank of America Corp DE lowered its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 59.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 362,517 shares of the company's stock after selling 533,765 shares during the quarter. Bank of America Corp DE's holdings in Takeda Pharmaceutical were worth $4,800,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TAK. First Trust Advisors LP grew its position in Takeda Pharmaceutical by 2.0% during the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock worth $42,910,000 after purchasing an additional 62,718 shares during the period. Van ECK Associates Corp boosted its stake in shares of Takeda Pharmaceutical by 1.6% in the fourth quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company's stock worth $29,266,000 after buying an additional 35,192 shares during the last quarter. Northern Trust Corp grew its holdings in Takeda Pharmaceutical by 14.6% during the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock worth $24,806,000 after acquiring an additional 238,161 shares during the period. Summit Global Investments raised its position in Takeda Pharmaceutical by 75.5% during the fourth quarter. Summit Global Investments now owns 729,200 shares of the company's stock valued at $9,655,000 after acquiring an additional 313,642 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Takeda Pharmaceutical by 15,449.0% in the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock valued at $6,629,000 after acquiring an additional 497,457 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock traded up $0.21 during trading on Friday, reaching $15.01. The company had a trading volume of 1,725,292 shares, compared to its average volume of 1,937,971. The firm has a market capitalization of $47.76 billion, a PE ratio of 37.53, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The firm's 50-day simple moving average is $14.66 and its 200 day simple moving average is $14.05. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.